Arcellx - ACLX Earnings per share for the last twelve months

Official company branding of Arcellx, Inc. (ACLX)

Positive trial results for CAR-T therapy in myeloma are creating current momentum, yet Arcellx operational processes rely on external CRO and CMO contractors. The fundamental EPS TTM metric visualizes capital accumulation phases, where -4.05 shows the value of this parameter. This underscores the status of an innovator creating safe cell engineering to save patients in critical conditions.

ACLX Arcellx Therapeutics Net earnings per one share for the last twelve months (04/28/2023 - 05/09/2026)

Summary analytical data breakdowns for Arcellx Inc (ACLX)

- current quotes and average value forecast:
Price Chart Arcellx|ACLX - Price Target Chart
- issuer market value details:
Market Value Arcellx, Inc.|ACLX - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share Arcellx|ACLX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio arcellx.com|ACLX - Total Business Assets
- debt and liquidity details:
Total Debt to Capital Arcellx|ACLX - Long-Term Debt to Capital|Short-Term Debt to Equity Arcellx Corp|ACLX - Aggregate Debt Obligations|Debts to Book Capitalization Arcellx, Inc.|ACLX - Company Long-Term Liabilities|Company Short-Term Debts Arcellx|Quick Liquidity arcellx.com
- earnings and multiples data:
ACLX - Company Net Income|Expected Profit Arcellx|ACLX - Price to Earnings Ratio|Projected Price to Earnings Arcellx, Inc.|ACLX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Arcellx, Inc.|ACLX - Operating profit EBITDA|Net earnings per share (EPS TTM) Arcellx|ACLX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months arcellx.com|ACLX - Earnings per share growth in current year|Expected earnings per share growth for next year Arcellx
General company analysis:Arcellx (ACLX)
Manufactured products of Arcellx Corp

EPS TTM is calculated as the ratio of total annual net income to the number of shares outstanding, allowing for an assessment of the business's real profitability without market noise. By analyzing the EPS TTM dynamics of Arcellx (ACLX), an investor can see how R&D efficiency and the logistical stability of CAR-T therapy manufacturing partners convert into actual financial results per share of capital.

Competitor analysis

TGTX - Earnings per share for the last twelve months|IRON: Earnings per share for the last twelve months|Syndax Pharmaceuticals, Inc. (SNDX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kura Oncology Inc (KURA)|Earnings per share for the last twelve months ADC Therapeutics Corp|Net earnings per one share for the last twelve months Foghorn FHTX|Net earnings per share (EPS TTM) VOR|nkartatx.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) COEP (Coeptis Therapeutics, Inc.)|Net earnings per share (EPS TTM) Actinium Pharma ATNM|ESLA - Earnings per share for the last twelve months|Earnings per share for the trailing year CASI (CASI Pharmaceuticals)|MRKR: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months in8bio.com|ERNA (Eterna Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months GT Biopharma Inc GTBP|Earnings per share for the last twelve months Aptose Biosciences Inc. (APTO)|Earnings per share for the last twelve months BPTH (Bio-Path Holdings, Inc)|Earnings per share for the last twelve months MEI Pharma, Inc. MEIP|Vincerx Pharma Inc. - Earnings per share for the last twelve months